US Bancorp DE Acquires 21,744 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)

US Bancorp DE boosted its stake in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 21.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 124,332 shares of the company's stock after buying an additional 21,744 shares during the quarter. US Bancorp DE's holdings in Takeda Pharmaceutical were worth $1,646,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the stock. Public Employees Retirement System of Ohio bought a new position in shares of Takeda Pharmaceutical in the 3rd quarter worth about $601,000. QRG Capital Management Inc. lifted its stake in Takeda Pharmaceutical by 16.8% in the fourth quarter. QRG Capital Management Inc. now owns 329,644 shares of the company's stock valued at $4,364,000 after buying an additional 47,490 shares during the period. Verition Fund Management LLC bought a new position in shares of Takeda Pharmaceutical during the 3rd quarter worth approximately $1,533,000. HighTower Advisors LLC grew its position in shares of Takeda Pharmaceutical by 199.5% during the 3rd quarter. HighTower Advisors LLC now owns 122,587 shares of the company's stock worth $1,744,000 after buying an additional 81,653 shares during the period. Finally, XTX Topco Ltd bought a new stake in shares of Takeda Pharmaceutical in the 3rd quarter valued at $957,000. Institutional investors own 9.17% of the company's stock.

Takeda Pharmaceutical Stock Up 0.2 %

NYSE TAK traded up $0.04 on Wednesday, hitting $14.94. 1,361,630 shares of the company were exchanged, compared to its average volume of 1,815,748. Takeda Pharmaceutical Company Limited has a 12 month low of $12.57 and a 12 month high of $15.22. The company has a current ratio of 1.31, a quick ratio of 0.72 and a debt-to-equity ratio of 0.63. The company has a market cap of $47.52 billion, a PE ratio of 37.34, a PEG ratio of 0.24 and a beta of 0.46. The stock has a fifty day moving average of $13.66 and a 200-day moving average of $13.90.

Remove Ads

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last released its quarterly earnings data on Thursday, January 30th. The company reported $0.42 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.34 by $0.08. Takeda Pharmaceutical had a net margin of 4.53% and a return on equity of 9.39%. As a group, analysts forecast that Takeda Pharmaceutical Company Limited will post 1.64 earnings per share for the current year.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.